Compare SNDX & STRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | STRA |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2016 | 1996 |
| Metric | SNDX | STRA |
|---|---|---|
| Price | $21.32 | $80.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 2 |
| Target Price | $80.23 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 1.2M | 157.5K |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 3.00% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.81 |
| Revenue | $111,304,000.00 | ★ $1,256,466,000.00 |
| Revenue This Year | $617.40 | $5.99 |
| Revenue Next Year | $115.70 | $3.79 |
| P/E Ratio | ★ N/A | $16.63 |
| Revenue Growth | ★ 595.65 | 3.74 |
| 52 Week Low | $8.58 | $72.25 |
| 52 Week High | $22.73 | $104.51 |
| Indicator | SNDX | STRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 44.26 |
| Support Level | $20.00 | $79.50 |
| Resistance Level | $21.89 | $83.15 |
| Average True Range (ATR) | 1.07 | 2.70 |
| MACD | 0.00 | -0.64 |
| Stochastic Oscillator | 68.62 | 21.80 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.